New Ebola sub-strain

A rapidly escalating Ebola outbreak in central Africa has raised concerns that a new sub-strain may have jumped from fruit bats to humans, marking a possible fresh zoonotic transmission event. Health officials in the Democratic Republic of Congo (DRC) are racing to contain the spread as cases and deaths continue to rise.

The outbreak has already caused more than 200 deaths in the DRC, with hundreds more infections suspected. The World Health Organization (World Health Organization) has increased its risk assessment to “very high,” warning that transmission may have gone undetected for months before being identified.

Authorities believe the earliest known case was a nurse in eastern DRC, though researchers suspect the virus was circulating earlier. Case numbers have surged quickly since the outbreak was declared, making it one of the largest Ebola events recorded in recent years.

Scientists say the strain involved, Bundibugyo Ebola, is rare and previously seen only in limited outbreaks in Uganda and the DRC. Genetic findings suggest it differs significantly from earlier strains, and experts suspect wildlife—possibly fruit bats—may be the source, although this has not been confirmed.

Unlike previous major Ebola outbreaks, existing vaccines and treatments are not specifically designed for this variant. This has complicated response efforts, with health teams relying on supportive care and experimental approaches while vaccine adaptation is being explored.

Uganda has also confirmed several related cases, including infections linked to healthcare exposure and travel contacts. International patients have been evacuated for treatment or isolation, highlighting concerns about cross-border spread.

Experts warn that weak health infrastructure, delayed detection, and conflict-affected regions in eastern Congo have allowed the virus to spread more easily. While global risk remains lower due to transmission through bodily fluids rather than air, officials stress the need for coordinated international response and faster vaccine development efforts.